CMS Will Address Rebates And “Retail Class Of Trade” In AMP Regulation
This article was originally published in The Pink Sheet Daily
The agency commented on an HHS Office of Inspector General report that found inconsistencies in average manufacturer price calculations.
You may also be interested in...
The agency agrees with pharmacy groups that the pricing benchmarks would not be accurate; regulation development will be CMS’ initial focus.
Pharmacy trade group says average manufacturer prices should not be made public due to calculation inconsistencies.
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.